Poster Presentations 2025
All the posters shown in the Poster Hall at AMMF’s Hybrid European Cholangiocarcinoma Conference 2025 can be seen here.
Please note: This area is intended for HCPs only.
1. Waraporn Taweesin, Khon Kaen University, Thailand
Transcriptomics analysis of in vivo Opisthorchis viverrini: implications for Opisthorchiasis and O. viverrini-associated cholangiocarcinoma diagnostics and preventions
To view the poster, click here.
2. Euan Brennan, University of Edinburgh
Exploring bio-mechanical signals during iCCA initiation
To view the poster, click here.
3. Padma-Sheela Jayaraman, University of Nottingham
Niclosamide and Palbociclib act synergistically to reduce cholangiocarcinoma cell viability in vitro and inhibit tumour growth in a mouse model
To view the poster, click here.
4. Ghada Nouairia, Karolinska Institutet, Sweden
Genome-scale DNA methylation profiling of biliary tract cancersand inhibit tumour growth in a mouse model
To view the poster, click here.
5. John Bridgewater, UCL Cancer Institute, University College London
A Phase 3, randomised study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01
To view the poster, click here.
6. John Bridgewater, UCL Cancer Institute, University College London
Baseline characteristics and progression free survival (PFS) of UK patients with IDH1 mutated cholangiocarcinoma: initial results from the phase 3b ProvIDHe study
To view the poster, click here.
7. Vasin Thanasukarn, Khon Kaen University, Thailand
Central bisectionectomy with hilar and caudate resection as a treatment option in perihilar cholangiocarcinoma with limited future liver remnant
To view the poster, click here.
8. Vasin Thanasukarn, Khon Kaen University, Thailand
Improving postoperative survival in cholangiocarcinoma: development of surgical strategies with a screening program in the epidemic region
To view the poster, click here.
9. Vasin Thanasukarn, Khon Kaen University, Thailand
Chemotherapy and surgical re-section in recurrent cholangiocarcinoma: a case report
To view the poster, click here.
10. Kemi Kostrzynski, AstraZeneca UK
Understanding the referral pathway for cancer of unknown primary with an ultimate diagnosis of biliary tract cancer
To view the poster, click here.
11. Athitaya Faipan, Khon Kaen University, Thailand
Mitochondrial genetic variations in cholangiocarcinoma cell lines
To view the poster, click here.
12. Arporn Wangwiwatsin, Khon Kaen University, Thailand
Investigation of genetic background markers for prognosis and precision medicine in Opisthorchis viverrini -associated cholangiocarcinoma
To view the poster, click here.
13. India Ellis, Royal Free London NHS Foundation Trust
The changing landscape of advanced cholangiocarcinoma therapy at The Royal Free London NHS Foundation Trust between 2021 and 2025
To view the poster, click here.
14. Panupong Chongwichai, Khon Kaen University, Thailand
Effect of parboiled germinated brown rice extract on CCA cell lines
To view the poster, click here.
15. Jirattiporn Thanuma, Khon Kaen University, Thailand
A metabolomics approach to investigating anticancer agents in dill (Anethum graveolens L.) extracts
To view the poster, click here.
16. Ramis Andaleeb, University College London Hospital
Impact of bone metastases in biliary tract cancer
To view the poster, click here.
17. Poramate Klanrit, Khon Kaen University, Thailand
Development of in vitro 3D cholangiocarcinoma model for personalized drug evaluation
To view the poster, click here.
18. Apiwat Jareanrat, Khon Kaen University, Thailand
Endobiliary radiofrequency ablation in recurrence and unresectable perihilar cholangiocarcinoma
To view the poster, click here.
19. Supattra Sripukdee, Khon Kaen University, Thailand
Effects of postoperative recovery program on self-efficacy, quality of postoperative recovery, and postoperative complications among patients with cholangiocarcinoma
To view the poster, click here.
20. Ngoma Onwuneme, Jazz Pharmaceuticals
HERIZON-BTC-302: A Phase 3 study of Zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
To view the poster, click here.
Back to previous page
